(Q36821171)

English

Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma

scientific article published on September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

malignant pleural mesothelioma

1 reference

based on heuristic

inferred from title

17

object named as

Fred R Hirsch

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

author name string

Daniel C Christoph

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Bernadette Reyna Asuncion

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Celine Mascaux

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Cindy Tran

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Xian Lu

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Murry W Wynes

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Thomas C Gauler

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jeremias Wohlschlaeger

8

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Dirk Theegarten

9

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Volker Neumann

10

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Rodrigo Hepp

11

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Stefan Welter

12

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Georgios Stamatis

13

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Andrea Tannapfel

14

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Martin Schuler

15

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Wilfried E Eberhardt

16

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

publication date

1 September 2012

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Journal of Thoracic Oncology

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1440-1448

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

The proof and measurement of association between two things

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

A monoclonal antibody for detection of folylpolyglutamate synthetase in paraffin embedded tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Significance of thymidylate synthase for resistance to pemetrexed in lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Assessment of tumor response in malignant pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Emerging drugs for mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Molecular basis of antifolate resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Pleural mesothelioma: little evidence, still time to do trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Index for rating diagnostic tests

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Pharmacology and mechanism of action of pemetrexed.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Resistance to antifolates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Molecular analysis of murine leukemia cell lines resistant to 5, 10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Human cytosolic and mitochondrial folylpolyglutamate synthetase are electrophoretically distinct. Expression in antifolate-sensitive and -resistant human cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Folylpolyglutamate synthetase expression in antifolate-sensitive and -resistant human cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Posttranscriptionally mediated decreases in folylpolyglutamate synthetase gene expression in some folate analogue-resistant variants of the L1210 cell. Evidence for an altered cognate mRNA in the variants affecting the rate of de novo synthesis of t

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

29 September 2017

Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

5 September 2018

Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

5 September 2018

Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

5 September 2018

Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

5 September 2018

Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

5 September 2018

CT, RECIST, and malignant pleural mesothelioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

5 September 2018

Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

5 September 2018

Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

5 September 2018

Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

5 September 2018

Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645940

4 December 2018

Malignant pleural mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22895141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/22895141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22895141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22895141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ERCC1 and non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22895141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/JTO.0B013E318260DEAA

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36821171&oldid=1878996696"